Zhongsheng Pharmaceutical: The company's non-public offering of A shares still needs to be approved by the China Securities Regulatory Commission. The company is concentrating on promoting the phase III clinical research of RAY1216 tablets
Zhongsheng Pharmaceutical: The company's non-public offering of A shares still needs to be approved by the China Securities Regulatory Commission. The company is concentrating on promoting the phase III clinical research of RAY1216 tablets https://whatchinareads.com/article/?uid=64ae8a209d1511edb04ec7fcafaebade
2023-01-26: [Chinese Article Link] On January 24, Zhongsheng Pharmaceutical said on the interactive platform that the company is continuing to promote the non-public offering of A-shares. The company has received the Notice of Second Feedback Opinions on the Review of Administrative Licensing Projects by the China Securities Regulatory
Note: This is a machine translated version of the Chinese news media article. A mature and nuanced reading is suggested.
Trending in China
- China
- Nie Xiaoyu
- Unilateral Sanctions
- United States
- Who
- Baiyun Airport
- Chinese Communist Party History Exhibition Hall
- Foreign Affairs
- Taiwan Province
- Zhuzhou Branch
- Mu Forest Farm
- Guangzhou Metro
- Peaceful Resolution
- Zhang Zhongmou
- Jiangxi
- Tsai Ing
- Yang Wenbin
- Ideal L8
- Tianjin Binhai New Area
- Jia Yueting
- Chairman Mao Memorial Hall
- Shenhua Ningxia Coal Group
- National Security Advisor
- Shanghai Metro
- Asia｜li Qiang
- Hunan Department
- Rural Development
- Dongfang City
- Hainan Province
- Boao Forum
Zhongsheng Pharmaceutical: The company's non-public offering of A shares still needs to be approved by the China Securities Regulatory Commission. The company is concentrating on promoting the phase III clinical research of RAY1216 tablets
Zhongsheng Pharmaceutical: The company's non-public offering of A shares still needs to be approved by the China Securities Regulatory Commission. The company is concentrating on promoting the phase III clinical research of RAY1216 tablets https://whatchinareads.com/article/?uid=64ae8a209d1511edb04ec7fcafaebade
2023-01-26: [Article Link] On January 24, Zhongsheng Pharmaceutical said on the interactive platform that the company is continuing to promote the non-public offering of A-shares. The company has received the Notice of Second Feedback Opinions on the Review of Administrative Licensing Projects by the China Securities Regulatory
Note: This is a translated version of the Chinese news media article. A mature and nuanced reading is suggested.